Device Trial Radar · NCT03125460
Clinical Evaluation of a Test for Monitoring the Recurrence of Bladder Cancer
Last checked: Nov 20, 2026Latest source record: Feb 7, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
424
Actual
Start
Dec 2016
Primary completion
Feb 2019
Study completion May 2019
Sponsor
- Lead sponsor
- CepheidNot on our public-company list
- Sponsor type
- Industry
- First posted
- Apr 24, 2017
Design
- Study type
- Observational
- Who can join
- All sexes, from 40 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to establish the performance characteristics of an assay that detects the recurrence of bladder cancer in patients previously diagnosed with bladder cancer. The study is conducted at locations within and outside of the United States. Testing is performed on urine specimens provided by eligible enrolled patients. Results from this study will not be used for patient management decisions.
Conditions
- Bladder Cancer
Interventions
Xpert Bladder Cancer MonitorDevice
in vitro diagnostic test for the recurrence of bladder cancer in patients that have been previously diagnosed with bladder cancer
Primary outcomes
What the sponsor says the trial is designed to measure.
- Comparison to histology for positive or suspicious cystoscopyTime frame: Baseline = Subject Enrollment
- Comparison to histology for positive or suspicious cystoscopyTime frame: Follow up = 12 months from Subject Enrollment (Baseline)
Locations
17 sites in 3 countries. Site status is shown where the registry gives one.
PAVA
Palo Alto, California
The Urology Center of Colorado, P.C.
Denver, Colorado
Urology Associates, P.C.
Englewood, Colorado
14 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.